Patents Assigned to NephroGenex, Inc.
  • Inhibitors of advanced glycation end products
    Patent number: 9428533
    Abstract: The present invention provides compounds of the formula, wherein A, B, G, R2, R6, and X are defined herein, pharmaceutical compositions of the same, and methods for treating or inhibiting development of AGE- and/or ALE-associated complications in subjects in need thereof.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: August 30, 2016
    Assignee: Nephrogenex, Inc
    Inventors: Raja G. Khalifah, Roger E. Marti
  • Inhibitors of Advanced Glycation End Products
    Publication number: 20140187506
    Abstract: The present invention provides compounds of the formula, wherein A, B, G, R2, R6, and X are defined herein, pharmaceutical compositions of the same, and methods for treating or inhibiting development of AGE- and/or ALE-associated complications in subjects in need thereof.
    Type: Application
    Filed: February 20, 2014
    Publication date: July 3, 2014
    Applicant: NephroGenex, Inc.
    Inventors: Raja G. Khalifah, Roger E. Marti
  • Pyridoxamine for the Treatment of Diabetic Kidney Disease
    Publication number: 20140171472
    Abstract: The present invention provides pharmaceutical compositions comprising dosage units of pyridoxamine, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, and methods for their use in limiting the progression of renal disease and/or diabetic complications in human diabetic patient.
    Type: Application
    Filed: February 20, 2014
    Publication date: June 19, 2014
    Applicant: NephroGenex, Inc.
    Inventors: Thorsten Degenhardt, Robert Schotzinger, J. Wesley Fox
  • Inhibitors of Advanced Glycation End Products
    Publication number: 20130178480
    Abstract: The present invention provides compounds of the formula, wherein A, B, G, R2, R6, and X are defined herein, pharmaceutical compositions of the same, and methods for treating or inhibiting development of AGE- and/or ALE-associated complications in subjects in need thereof.
    Type: Application
    Filed: February 14, 2013
    Publication date: July 11, 2013
    Applicant: NephroGenex, Inc.
    Inventor: NephroGenex, Inc.
  • Methods for the synthesis of pyridoxamine
    Patent number: 8431712
    Abstract: The invention provides non-oxidative methods for the large scale manufacture of pyridoxamine (I) (4-aminomethyl-3-hydroxy-5-hydroxymethyl-2-methylpyridine): and salts thereof. The invention also provides intermediate compounds for the synthesis of pyridoxamine, as well as compositions and methods for the treatment and/or prevention of conditions associated with the formation of post-Amadori advanced glycation end-products.
    Type: Grant
    Filed: August 12, 2010
    Date of Patent: April 30, 2013
    Assignee: NephroGenex, Inc.
    Inventors: Raja G. Khalifah, Roland Keilitz, Christoph Koellner, Thorsten Degenhardt, Stephen Robert Brand
  • Pyridoxamine for the Treatment of Diabetic Kidney Disease
    Publication number: 20130011379
    Abstract: The present invention provides pharmaceutical compositions comprising dosage units of pyridoxamine, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, and methods for their use in limiting the progression of renal disease and/or diabetic complications in human diabetic patient.
    Type: Application
    Filed: April 13, 2012
    Publication date: January 10, 2013
    Applicant: NEPHROGENEX, INC.
    Inventors: Thorsten Degenhardt, Robert Schotzinger, Wesley J. Fox
  • Pyridoxamine for the treatment of diabetic intermediaries and post-amadori inhibition
    Patent number: 8067444
    Abstract: The present invention provides pharmaceutical compositions comprising dosage units of pyridoxamine, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, and methods for their use in limiting the progression of renal disease and/or diabetic complications in human diabetic patient.
    Type: Grant
    Filed: January 25, 2008
    Date of Patent: November 29, 2011
    Assignee: NephroGenex, Inc.
    Inventors: Degenhardt Thorsten, Schotzinger Robert, Fox J. Wesley
  • Inhibitors of Advanced Glycation End Products
    Publication number: 20110245269
    Abstract: The present invention provides compounds of the formula, wherein A, B, G, R2, R6, and X are defined herein, pharmaceutical compositions of the same, and methods for treating or inhibiting development of AGE- and/or ALE-associated complications in subjects in need thereof.
    Type: Application
    Filed: December 9, 2010
    Publication date: October 6, 2011
    Applicant: NephroGenex, Inc.
    Inventors: Raja G. Khalifah, Roger E. Marti